Table 1.
Baseline demographic and clinical characteristics of the population with Inflammatory Bowel Disease.
| Variables | Mean ± SD |
|---|---|
| Age (years) | 44 ± 13 |
| IBD duration (years) | 8 ± 7 |
| Follow-up time (months) | 48 ± 3 |
| HBI | 1.2 ± 1.9 |
| MCI | 0.9 ± 1.6 |
| SES-CD | 2.5 ± 1.2 |
| Rutgeerts score * | 1.5 ± 0.5 |
| Weight (Kg) | 71 ± 11 |
| BMI (Kg/m2) | 25 ± 3 |
| Glucose (mg/dL) | 95 ± 20 |
| Insulin (μIU/ml) | 11 ± 6 |
| HOMA-IR | 1.6 ± 1.7 |
| Total Cholesterol (mg/dL) | 180 ± 44 |
| Triglycerides (mg/dL) | 118 ± 70 |
| HDL Cholesterol (mg/dL) | 54 ± 17 |
| LDL Cholesterol (mg/dL) | 116 ± 33 |
| AST (IU/L) | 19 ± 7 |
| ALT (IU/L) | 21 ± 16 |
| γGT (IU/L) | 24 ± 17 |
| Total Bilirubin (mg/dL) | 0.63 ± 0.4 |
| CAP score (dB/m) | 237 ± 49 |
| IQR (%) | 11 ± 6 |
| Liver Stiffness (kPa) | 4.7 ± 1 |
| IQR (%) | 12 ± 7 |
| Prevalence | |
| Gender (Male, %) | 63 |
| Smokers (%) | 6 |
| Crohn’s disease (%) | 33 |
| Ulcerative colitis (%) | 67 |
| Overweight/Obesity (%) | 55 |
| T2DM (%) | 14 |
| CCS (%) | 6 |
| antiTNFα (%) | 18 |
| 5ASA (%) | 93 |
| AZA/6-MP (%) | 18 |
| Methotrexate (%) | 1 |
Note: IBD = inflammatory bowel disease; HBI = Harvey Bradshaw index; MCI = Mayo clinic idex; BMI = body mass index; HOMA-IR = homeostatic model assessment for insulin resistance; HDL = high-density lipoprotein; LDL = low-density lipoprotein; AST = aspartate aminotransferase; ALT = alanine aminotransferase; γGT = gamma glutamyltransferase; CAP = controlled attenuation parameter; IQR = interquartile range; T2DM = type 2 diabetes mellitus; CCS = corticosteroids; antiTNFα = anti-tumour necrosis factor α antibodies; 5ASA = mesalamine; AZA/6-MP = azathioprine/6 -mercaptopurine. * four participants.